Squarepoint Ops LLC Has $656,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Squarepoint Ops LLC lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 208.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,664 shares of the company's stock after purchasing an additional 11,929 shares during the quarter. Squarepoint Ops LLC's holdings in Amphastar Pharmaceuticals were worth $656,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after buying an additional 105,288 shares in the last quarter. Boston Trust Walden Corp lifted its position in Amphastar Pharmaceuticals by 81.4% in the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Northern Trust Corp boosted its stake in Amphastar Pharmaceuticals by 5.1% in the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company's stock worth $22,767,000 after purchasing an additional 29,808 shares during the period. Marshall Wace LLP boosted its stake in Amphastar Pharmaceuticals by 7.1% in the 4th quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock worth $22,601,000 after purchasing an additional 40,212 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Amphastar Pharmaceuticals by 7.4% during the 4th quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock worth $19,512,000 after purchasing an additional 36,100 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Price Performance

AMPH stock traded down $0.40 during mid-day trading on Thursday, hitting $25.47. The stock had a trading volume of 295,723 shares, compared to its average volume of 484,601. The firm has a fifty day simple moving average of $24.75 and a 200 day simple moving average of $31.84. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.20 billion, a P/E ratio of 8.47, a P/E/G ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.